ALK-positive histiocytosis with central nervous system involvement successfully treated with alectinib: a rare case report

Zurück zum Zitat Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia 36(7):1703–1719 Epub 2022/06/23. https://doi.org/10.1038/s41375-022-01613-1CrossRefPubMedPubMedCentral Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia 36(7):1703–1719 Epub 2022/06/23. https://​doi.​org/​10.​1038/​s41375-022-01613-1CrossRefPubMedPubMedCentral

Zurück zum Zitat Kemps PG, Picarsic J, Durham BH, Helias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, van de Wetering MD, van Noesel CJM, van Laar JAM, Verdijk RM, Flucke UE, Hogendoorn PCW, Woei AJF, Sciot R, Beilken A, Feuerhake F, Ebinger M, Mohle R, Fend F, Bornemann A, Wiegering V, Ernestus K, Mery T, Gryniewicz-Kwiatkowska O, Dembowska-Baginska B, Evseev DA, Potapenko V, Baykov VV, Gaspari S, Rossi S, Gessi M, Tamburrini G, Heritier S, Donadieu J, Bonneau-Lagacherie J, Lamaison C, Farnault L, Fraitag S, Jullie ML, Haroche J, Collin M, Allotey J, Madni M, Turner K, Picton S, Barbaro PM, Poulin A, Tam IS, El Demellawy D, Empringham B, Whitlock JA, Raghunathan A, Swanson AA, Suchi M, Brandt JM, Yaseen NR, Weinstein JL, Eldem I, Sisk BA, Sridhar V, Atkinson M, Massoth LR, Hornick JL, Alexandrescu S, Yeo KK, Petrova-Drus K, Peeke SZ, Munoz-Arcos LS, Leino DG, Grier DD, Lorsbach R, Roy S, Kumar AR, Garg S, Tiwari N, Schafernak KT, Henry MM, van Halteren AGS, Abla O, Diamond EL, Emile JF (2022) ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 139(2):256–280 Epub 2021/11/03. https://doi.org/10.1182/blood.2021013338CrossRefPubMedPubMedCentral Kemps PG, Picarsic J, Durham BH, Helias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, van de Wetering MD, van Noesel CJM, van Laar JAM, Verdijk RM, Flucke UE, Hogendoorn PCW, Woei AJF, Sciot R, Beilken A, Feuerhake F, Ebinger M, Mohle R, Fend F, Bornemann A, Wiegering V, Ernestus K, Mery T, Gryniewicz-Kwiatkowska O, Dembowska-Baginska B, Evseev DA, Potapenko V, Baykov VV, Gaspari S, Rossi S, Gessi M, Tamburrini G, Heritier S, Donadieu J, Bonneau-Lagacherie J, Lamaison C, Farnault L, Fraitag S, Jullie ML, Haroche J, Collin M, Allotey J, Madni M, Turner K, Picton S, Barbaro PM, Poulin A, Tam IS, El Demellawy D, Empringham B, Whitlock JA, Raghunathan A, Swanson AA, Suchi M, Brandt JM, Yaseen NR, Weinstein JL, Eldem I, Sisk BA, Sridhar V, Atkinson M, Massoth LR, Hornick JL, Alexandrescu S, Yeo KK, Petrova-Drus K, Peeke SZ, Munoz-Arcos LS, Leino DG, Grier DD, Lorsbach R, Roy S, Kumar AR, Garg S, Tiwari N, Schafernak KT, Henry MM, van Halteren AGS, Abla O, Diamond EL, Emile JF (2022) ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 139(2):256–280 Epub 2021/11/03. https://​doi.​org/​10.​1182/​blood.​2021013338CrossRefPubMedPubMedCentral

Zurück zum Zitat Wang J, Zheng Y, Xiong Y Imaging features of ALK-positive histiocytosis with neurological involvement: a case report and literature review [Original Research]. Frontiers in Oncology. 2024 2024-February-22;14. English. https://doi.org/10.3389/fonc.2024.1333519 Wang J, Zheng Y, Xiong Y Imaging features of ALK-positive histiocytosis with neurological involvement: a case report and literature review [Original Research]. Frontiers in Oncology. 2024 2024-February-22;14. English. https://​doi.​org/​10.​3389/​fonc.​2024.​1333519

Zurück zum Zitat Cheah AL, Zou Y, Lanigan C, Billings SD, Rubin BP, Hornick JL, Goldblum JR (2019) ALK expression in Angiomatoid Fibrous Histiocytoma: a potential diagnostic pitfall. Am J Surg Pathol 43(1):93–101 Epub 2018/06/08. https://doi.org/10.1097/PAS.0000000000001103CrossRefPubMed Cheah AL, Zou Y, Lanigan C, Billings SD, Rubin BP, Hornick JL, Goldblum JR (2019) ALK expression in Angiomatoid Fibrous Histiocytoma: a potential diagnostic pitfall. Am J Surg Pathol 43(1):93–101 Epub 2018/06/08. https://​doi.​org/​10.​1097/​PAS.​0000000000001103​CrossRefPubMed

Zurück zum Zitat Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland A, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J (2018) Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol 29(6):1409–1416 Epub 2018/04/19. https://doi.org/10.1093/annonc/mdy121CrossRefPubMedPubMedCentral Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland A, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J (2018) Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol 29(6):1409–1416 Epub 2018/04/19. https://​doi.​org/​10.​1093/​annonc/​mdy121CrossRefPubMedPubMedCentral

Zurück zum Zitat Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E (2020) Brain penetration of Lorlatinib: cumulative incidences of CNS and Non-CNS progression with Lorlatinib in patients with previously treated ALK-Positive non-small-cell Lung Cancer. Target Oncol 15(1):55–65 Epub 2020/02/16. https://doi.org/10.1007/s11523-020-00702-4CrossRefPubMedPubMedCentral Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E (2020) Brain penetration of Lorlatinib: cumulative incidences of CNS and Non-CNS progression with Lorlatinib in patients with previously treated ALK-Positive non-small-cell Lung Cancer. Target Oncol 15(1):55–65 Epub 2020/02/16. https://​doi.​org/​10.​1007/​s11523-020-00702-4CrossRefPubMedPubMedCentral

Zurück zum Zitat Mousa DV, Mavrovounis G, Argyropoulos D, Stranjalis G, Kalamatianos T (2024) Anaplastic lymphoma kinase (ALK) in posterior cranial Fossa tumors: a scoping review of Diagnostic, Prognostic, and therapeutic perspectives. Cancers (Basel) 16(3). https://doi.org/10.3390/cancers16030650Cited in: Pubmed; PMID 38339401 Epub 2024/02/10 Mousa DV, Mavrovounis G, Argyropoulos D, Stranjalis G, Kalamatianos T (2024) Anaplastic lymphoma kinase (ALK) in posterior cranial Fossa tumors: a scoping review of Diagnostic, Prognostic, and therapeutic perspectives. Cancers (Basel) 16(3). https://​doi.​org/​10.​3390/​cancers16030650Cited in: Pubmed; PMID 38339401 Epub 2024/02/10

Zurück zum Zitat Rigaud C, Knorr F, Brugieres L, Woessmann W (2023) Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Best Pract Res Clin Haematol 36(1):101444 Epub 2023/03/13. https://doi.org/10.1016/j.beha.2023.101444CrossRefPubMed Rigaud C, Knorr F, Brugieres L, Woessmann W (2023) Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Best Pract Res Clin Haematol 36(1):101444 Epub 2023/03/13. https://​doi.​org/​10.​1016/​j.​beha.​2023.​101444CrossRefPubMed

Zurück zum Zitat Chennouf A, Arslanian E, Roberge D, Berthelet F, Bojanowski M, Bahary JP, Masucci L, Belanger K, Florescu M, Wong P (2017) Efficiency of Crizotinib on an ALK-Positive inflammatory myofibroblastic tumor of the Central Nervous System: a Case Report. Cureus 9(3):e1068 Epub 2017/04/15. https://doi.org/10.7759/cureus.1068CrossRefPubMedPubMedCentral Chennouf A, Arslanian E, Roberge D, Berthelet F, Bojanowski M, Bahary JP, Masucci L, Belanger K, Florescu M, Wong P (2017) Efficiency of Crizotinib on an ALK-Positive inflammatory myofibroblastic tumor of the Central Nervous System: a Case Report. Cureus 9(3):e1068 Epub 2017/04/15. https://​doi.​org/​10.​7759/​cureus.​1068CrossRefPubMedPubMedCentral

Zurück zum Zitat Lastowska M, Trubicka J, Karkucinska-Wieckowska A, Kaleta M, Tarasinska M, Perek-Polnik M, Sobocinska AA, Dembowska-Baginska B, Grajkowska W, Matyja E (2019) Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors. Brain Tumor Pathol 36(1):1–6 Epub 2018/12/14. https://doi.org/10.1007/s10014-018-0331-2CrossRefPubMed Lastowska M, Trubicka J, Karkucinska-Wieckowska A, Kaleta M, Tarasinska M, Perek-Polnik M, Sobocinska AA, Dembowska-Baginska B, Grajkowska W, Matyja E (2019) Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors. Brain Tumor Pathol 36(1):1–6 Epub 2018/12/14. https://​doi.​org/​10.​1007/​s10014-018-0331-2CrossRefPubMed